 |
||||||||||
 |
 |
|||||||||
 |
 |
 |
 |
 |
||||||
 |
 |
|||||||||
 |
||||||||||
 |
||||||||||
 |
||||||||||
 |
||||||||||
 |
||||||||||
 |
About CVBT | |||||||||
|
An estimated 81,100,000 American adults (more than 1 in 3) have one or more types of cardiovascular disease (CVD). Nearly 2,300 Americans die of CVD each day, an average of one death every 38 seconds.¹ Corporate Profile: Overview CardioVascular BioTherapeutics, Inc. (OTC: CVBT.PK) is a biopharmaceutical company developing protein drug candidates to address cardiovascular diseases including severe coronary heart disease, diabetic wounds, and peripheral artery disease. The active pharmaceutical ingredient (API) in our drug candidates is FGF-1, a human protein that stimulates the growth of new blood vessels, thereby increasing the blood supply to ischemic organs and tissues. Our lead drug candidate, (CVBT-141A) for the treatment of severe coronary heart disease, successfully completed a U.S. FDA authorized Phase I study. The FDA has authorized a Phase II study for which enrollment is underway. Click to learn more about our Phase II heart trial. Our pipeline also includes drug candidates for the treatment of diabetic wounds and peripheral artery disease. CardioVascular BioTherapeutics, Inc. is committed to conducting research & development to establish the positive effect of FGF-1 aimed at improving the quality of life for those suffering from cardiovascular disease.
¹American Heart Association, "Heart Disease and Stroke Statistics-2010 Update"
Use of
this site constitutes agreement to our Terms and Conditions | ||||||||||
 |
||||||||||
 |
|
|
|
|
|
|
|
|
|
|